NSE · THYROCARE
Thyrocare Technologies Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹226 Cr with net profit ₹50 Cr — a 22.23% net margin, versus 19.27% the period before.
Shareholding
As of 2026-09-30
- Promoter51.02%
- Public13.7%
- FII9.37%
- DII25.92%
75,186 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.93× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 9.91 percentage points to 51.02% in the latest disclosure.
Peer comparison
Healthcare · ranked #20 of 86 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Apollo Hospitals Enter. Limited | ₹1,12,785 Cr | 53.6 | 11.85 | 20.48% | 7.91% |
| Manipal Health Enterpri Limited | ₹82,040 Cr | 87.48 | 4.99 | 10.59% | 7.81% |
| Max Healthcare Institute Ltd. | ₹81,271 Cr | 54.29 | 7.56 | 13.42% | 16.73% |
| Aster DM Quality Care Ltd. | ₹56,502 Cr | 145.66 | 13.43 | 8.48% | 6.54% |
| Fortis Healthcare Ltd. | ₹55,467 Cr | 52 | 5.59 | 10.53% | 11.02% |
| Narayana Hrudayalaya Ltd. | ₹33,971 Cr | 39.41 | 7.48 | 17.76% | 9% |
| Global Health Limited | ₹32,588 Cr | 56.93 | 8.2 | 14.05% | 11.88% |
| Dr. Lal Path Labs Ltd. | ₹31,146 Cr | 55.37 | 12.4 | 20.13% | 18.75% |
| Krishna Institute of Medical Sciences Ltd. | ₹28,124 Cr | 134.73 | 7.5 | 10.74% | 4.85% |
| Dr. Agarwal's Health Care Limited | ₹15,068 Cr | 102.2 | 7.44 | 6.58% | 6.72% |
| Thyrocare Technologies Ltd.(this company) | ₹7,491 Cr | 41.43 | 14.63 | 27.85% | 20.13% |
AI analysis
AI-generated · google/gemini-2.5-flashThyrocare Technologies Ltd. (539871) operates in the Healthcare sector. The company provides diagnostic testing services, imaging services, and sells related consumables and equipment. Founded in 1996 and based in Navi Mumbai, India, it is a subsidiary of Docon Technologies Private Limited. The company reported revenue of Rs 829.04 Cr and a profit margin of 19.67%.
Positives
- +Revenue growth was 20.61%, indicating an increase in sales.
- +The profit margin of 19.67% suggests efficient conversion of revenue into profit.
- +Return on Equity (ROE) stood at 27.85%, demonstrating effective use of shareholder capital.
- +Return on Capital Employed (ROCE) was 33.90%, indicating efficient use of overall capital.
- +The debt-to-equity ratio was low at 0.07, suggesting limited reliance on debt financing.
Negatives
- −100% of promoter shares were pledged as of June 30, 2026.
- −The company is listed under 'ENCUMBRANCE' surveillance measures due to pledged shares.
Business Overview
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals across India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The Diagnostic Testing Services segment focuses on the sale of consumables for collection and promotion of pathology. The Imaging Services segment deals with radio-pharmaceuticals and consumables for reporting. The 'Others' segment includes the sale of testing equipment and consumables, along with glucometers and glucostrips under the 'sugarscan' brand.
Financial Performance
The company reported an annual revenue of Rs 829.04 Cr, reflecting a revenue growth of 20.61%. Over the last four reported quarters, revenue showed fluctuations, from Rs 193.03 Cr in Jun 2025 to Rs 223.95 Cr in Mar 2026. Net profit also varied, reaching Rs 47.12 Cr in Mar 2026.
Profitability & Returns
Thyrocare Technologies Ltd. achieved a profit margin of 19.67% and earnings per share (EPS) of Rs 10.1. The company's Return on Equity (ROE) was 27.85%, and Return on Capital Employed (ROCE) stood at 33.90%. These figures indicate the company's efficiency in generating profits relative to its equity and capital employed.
Balance Sheet
The company maintains a low debt-to-equity ratio of 0.07, suggesting a conservative approach to financing its operations. The book value per share is Rs 32.21. These metrics provide insight into the company's financial structure and its ability to cover its liabilities.
Ownership & Pledges
As of June 30, 2026, promoter shareholding was 60.9239%. DIIs held 20.9228% and FIIs held 5.4378% of the shares. Public shareholding was 12.7155%. A significant concern is that 100% of promoter shares were pledged as of the same date, with 'Docon Technologies Private Limited' pledging 96,969,696 shares.
Regulatory & Surveillance
The company is under 'ENCUMBRANCE' surveillance, which indicates the shares have been pledged or there are other restrictions on their transferability. Specifically, the 'ENCUMBRANCE' measure is listed, reinforcing the concern around pledged shares.
Data as of — price: 2026-10-27 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Thyrocare Technologies Ltd.share price & fundamentals